Xenon Pharmaceuticals Inc is a Canadian clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of therapeutics for orphan indications. The company has developed a gene therapy referred as Glybera for the treatment of a subset of patients with the orphan lipid disorder lipoprotein lipase deficiency. The other product candidates include TV-45070, GDC-0310, XEN801 and XEN901 and other compounds in preclinical and discovery pipeline.